Skip to main content

Table 2 Accumulation of vanadium (μg/g) in the liver, kidneys, and blood of vehicle-treated, sodium vanadate (SV)-treated, L-ascorbic acid (L-AA)-treated, and L-AA+SV-treated spinal muscular atrophy (SMA) mice

From: Sodium vanadate combined with l-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy

Groups Liver Kidney Blood
Postnatal day 6:    
SMA (vehicle) ND ND  
SMA (SV) 2.11 ± 0.18 3.89 ± 0.60  
SMA (L-AA) ND ND  
SMA (L-AA+SV) 0.59 ± 0.01 *** 1.37 ± 0.26 *  
Postnatal day 30:    
SMA (vehicle) ND ND ND
SMA (L-AA) ND ND ND
SMA (L-AA+SV) 0.22 ± 0.02 0.22 ± 0.04 0.07 ± 0.01
Postnatal day 90:    
SMA (vehicle) ND ND ND
SMA (L-AA) ND ND ND
SMA (L-AA+SV) 0.08 ± 0.04 0.07 ± 0.02 0.02 ± 0.01
  1. Results are reported as means of three mice in each group ± SEM. *P < 0.05 and ***P < 0.001 relative to SV. ND = not detectable (< 0.202 ng/g).